Key facts
- This page summarizes Jane Huang's Form 4 filing for BeiGene, Ltd. (ONC).
- 8 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 16 Dec 2021, 16:50.
Jane Huang - 14 Dec 2021 Form 4 Insider Report for BeiGene, Ltd. (ONC)
- Reporting relationship
- CMO, Hematology
- Issuer ticker
- ONC
- Reported as of
- 14 Dec 2021
- Net transaction value
- -$237,271
- SEC form
- 4
- Accepted by SEC
- 16 Dec 2021, 16:50:15 UTC
- Prior SEC filing
- 02 Dec 2021
- Next SEC filing
- 06 Apr 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Qing Nian, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jane Huang filed Form 4 for BeiGene, Ltd. (ONC) on 16 Dec 2021.
Change
- Previous filing in this sequence was filed on 02 Dec 2021.
- Current net transaction value: -$237,271.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BGNE
transaction
American Depositary Shares
Options Exercise
- Transaction value
- $179,940
- Shares
- +1,500
- Change %
- Price
- $119.96
- Shares after
- 1,500
- Date
- 14 Dec 2021
- Ownership
- Direct
- Footnotes
- F1
BGNE
transaction
American Depositary Shares
Sale
- Transaction value
- $82,361
- Shares
- -300
- Change %
- -20%
- Price
- $274.54
- Shares after
- 1,200
- Date
- 14 Dec 2021
- Ownership
- Direct
- Footnotes
- F1, F2, F3
BGNE
transaction
American Depositary Shares
Sale
- Transaction value
- $83,086
- Shares
- -300
- Change %
- -25%
- Price
- $276.95
- Shares after
- 900
- Date
- 14 Dec 2021
- Ownership
- Direct
- Footnotes
- F1, F2, F4
BGNE
transaction
American Depositary Shares
Sale
- Transaction value
- $139,106
- Shares
- -500
- Change %
- -56%
- Price
- $278.21
- Shares after
- 400
- Date
- 14 Dec 2021
- Ownership
- Direct
- Footnotes
- F1, F2, F5
BGNE
transaction
American Depositary Shares
Sale
- Transaction value
- $27,879
- Shares
- -100
- Change %
- -25%
- Price
- $278.79
- Shares after
- 300
- Date
- 14 Dec 2021
- Ownership
- Direct
- Footnotes
- F1, F2
BGNE
transaction
American Depositary Shares
Sale
- Transaction value
- $56,327
- Shares
- -200
- Change %
- -67%
- Price
- $281.64
- Shares after
- 100
- Date
- 14 Dec 2021
- Ownership
- Direct
- Footnotes
- F1, F2, F6
BGNE
transaction
American Depositary Shares
Sale
- Transaction value
- $28,452
- Shares
- -100
- Change %
- -100%
- Price
- $284.52
- Shares after
- 0
- Date
- 14 Dec 2021
- Ownership
- Direct
- Footnotes
- F1, F2
BGNE
holding
Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 160,055
- Date
- 14 Dec 2021
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BGNE
transaction
Derivative
Share Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -19,500
- Change %
- -8.4%
- Price
- $0.000000
- Shares after
- 211,276
- Date
- 14 Dec 2021
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 19,500
- Exercise price
- $9.23
- Footnotes
- F7, F8
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 8 footnotes
Footnote F1
Each American Depositary Share represents 13 Ordinary Shares.
Footnote F2
The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 17, 2018, as most recently amended on December 15, 2020.
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $274.27 to $274.70, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
Footnote F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $276.57 to $277.37, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
Footnote F5
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $277.78 to $278.67, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
Footnote F6
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $281.49 to $281.78, inclusive. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price.
Footnote F7
The number of securities underlying the option and the exercise price therefor are represented in ordinary shares.
Footnote F8
These securities vest over a four-year period as follows: 25% on June 5, 2020, and the remaining in 36 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon certain termination events following a change in control.